“Fast but not so furious”: A condensed step‐up dosing schedule of teclistamab for relapsed/refractory multiple myeloma
Abstract Teclistamab is a B‐cell maturation antigen (BCMA)‐directed bispecific T‐cell engager approved for relapsed‐refractory multiple myeloma (RRMM). Cytokine release syndrome (CRS) and Immune effector cell‐associated neurotoxicity syndrome (ICANS) are well‐documented treatment ‐related adverse ev...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wiley
2024-08-01
|
| Serie: | eJHaem |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1002/jha2.906 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|